Acute urinary retention due to benign prostate hyperplasia (BPH) Sudden inability to urinate caused by benign prostatic enlargement
Conditions
Interventions
Intervention: TWOC on day 3. Control: TWOC on day 14.
Sponsors
Isala
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Adult man;Diagnosed with acute urinary retention (AUR( treated with a transurethral catheter (TUC) and alpha-blocker therapy;Mentally competent and understanding of benefits and potential burden of the study;Written or digital informed consent.
Exclusion criteria
Exclusion criteria: A failed prior TWOC, urinary retention >1500ml, usage of an alpha-blocker other than tamsulosin, silodosin or alfuzosin, neurogenic bladder dysfunction (e.g. multiple sclerosis, spinal cord injury, spina bifida, vertebral disc prolapse), history of prostate cancer (ISUP grade group = 2), active bladder cancer or undergoing follow-up for bladder cancer, urinary retention following surgery (within 72 hours post-operation), history of lower urinary tract surgery (e.g., bladder augmentation, urethral surgery, prostate surgery), bladder stones, suspected urethral stricture, clot retention, urosepsis or a contra-indication for alpha blocker therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Re-catheterization rate immediately after TWOC (success vs. failure of spontaneous voiding). | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient-centered outcomes (symptoms, QoL), complications, and both healthcare and societal costs. | — |
Countries
Netherlands
Contacts
Public ContactL.L.A. Ribbert
Isala
Outcome results
None listed